CpG motifs in bacterial DNA and their immune effects

Annual Review of Immunology

Volumn 20, Issue , 2002, Pages 709-760

  Krieg, Arthur M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BACTERIAL DNA; CHEMOKINE; CYTOKINE; DNA VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ALLERGY; ANIMAL MODEL; ANTIGEN RECOGNITION; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CPG ISLAND; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOSOME; GENETIC PREDISPOSITION; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; NATURAL KILLER CELL; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; VACCINATION;

ANIMALS; B-LYMPHOCYTES; BACTERIA; CANCER VACCINES; CPG ISLANDS; DENDRITIC CELLS; DNA METHYLATION; DNA, BACTERIAL; HUMANS; HYPERSENSITIVITY; KILLER CELLS, NATURAL; MACROPHAGES; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; NEOPLASMS; NEUTROPHILS; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VACCINES, DNA;

EID: 0036219195     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.20.100301.064842     Document Type: Review

References (299)

1. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity
2. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: Role of IRF-1 and NF-kappaB
3. CpG islands as gene markers in the vertebrate nucleus
4. CpG motifs in bacterial DNA trigger direct B-cell activation
5. Innate immunity: Impact on the adaptive immune response
6. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
7. Adjuvant immunotherapy in superficial bladder cancer
8. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity
9. In vitro augmentation of natural killer cell activity and production of interferon-α/β and -γ with deoxyribonucleic acid fraction from Mycobacterium bovis BCG
10. How BCG led to the discovery of immunostimulatory DNA
11. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth
12. Oligonucleotide sequences required for natural killer cell activation
13. A synthetic single-stranded DNA, poly(dG,dC), induces interferon-α/β and -γ, augments natural killer activity, and suppresses tumor growth
14. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
15. The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens
16. The influence of base sequence on the immunological properties of defined oligonucleotides
17. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides
18. Genomic DNA released by dying cells induces the maturation of APCs
19. An antisense oligonucleotide complementary to a sequence in Ig 2b increases γ 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion
20. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1
21. Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus
22. A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-κB p65 causes sequence-specific immune stimulation
23. Analysis of thymic endogenous retroviral expression in murine lupus. Genetic and immune studies
24. A role for endogenous retroviral sequences in the regulation of lymphocyte activation
25. Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improves efficacy
26. Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner
27. Leukocyte stimulation by oligodeoxynucleotides
28. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs
29. Selection of antisense oligonucleotides on the basis of genomic frequency of the target sequence
30. DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B cells
31. + T cells: Implications for tumor immunotherapy
32. Mitogenicity of DNA from different organisms for murine B cells
33. Heterogeneity of genomes: Measures and values
34. Selection against CpG dinucleotides in lentiviral genes: A possible role of methylation in regulation of viral expression
35. Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA
36. Causal analysis of CpG suppression in the Mycoplasma genome
37. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry
38. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved
39. Mechanism and function of a newly identified CpG DNA motif in human primary B cells
40. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-γ production in vitro
41. Mammalian granulocyte-macrophage colony-stimulating factor and some CpG motifs have an effect on the immunogenicity of DNA and subunit vaccines in fish
42. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
43. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
44. Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity
45. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides
46. Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides
47. High expression of a 3′-5′ exonuclease activity is specific to B lymphocytes
48. Activation of human B cells by phosphorothioate oligodeoxynucleotides
49. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
50. Physicochemical properties of phosphorothioate oligodeoxynucleotides
51. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?
52. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides
53. Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors
54. In vitro cellular uptake, distribution, and metabolism of oligonucleotides
55. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides
56. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase
57. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism
58. Inhibition of high-affinity basic fibroblast growth factor binding by oligonucleotides
59. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix
60. Phosphorothioate oligodeoxynucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo
61. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding
62. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides
63. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: Dependence on phosphorothioate modification and reversal by heparin
64. Immune stimulation - A class effect of phosphorothioate oligodeoxynucleotides in rodents
65. Increased potency of an aptameric G-rich oligonucleotide is associated with novel functional properties of phosphorothioate linkages
66. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice
67. Effect of different chemically modified oligodeoxynucleotides on immune stimulation
68. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs
69. Bacterial/CpG DNA down-modulates colony stimulating factor-1 receptor surface expression on murine bone marrow-derived macrophages with concomitant growth arrest and factor-independent survival
70. Characterization and modulation of immune stimulation by modified oligonucleotides
71. Enzymatic synthesis of stereoregular (all Rp) oligonucleotide phosphorothioate and its properties
72. Stereo-enriched phosphorothioate oligodeoxynucleotides: Synthesis, biophysical and biological properties
73. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity
74. Type I interferon-mediated stimulation of T cells by CpG DNA
75. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
76. Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines
77. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs
78. Distinct CpG DNA and polyinosinicpolycytidylic acid double-stranded RNA, respectively, stimulate CD11c(-) type 2 dendritic cell precursors and CD11c(+) dendritic cells to produce type I IFN
79. Phosphorothioate backbone modification modulates macrophage activation by CpG DNA
80. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus
81. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells
82. Now I know my CpGs
83. Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN
84. Immunostimulatory properties of genomic DNA from different bacterial species
85. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles
86. Macrophages ingest and are activated by bacterial DNA
87. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines
88. Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs
89. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kB activation
90. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
91. Evaluation of the protective efficacy of rabies DNA vaccine in mice using an intracerebral challenge model
92. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons
93. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid: pDNA complexes
94. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors
95. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway
96. Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides
97. Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12
98. Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides
99. IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides
100. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
101. Immunostimulatory DNA pre-priming: A novel approach for prolonged Th1-biased immunity
102. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells
103. Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-contalning oligodeoxynucleotide motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion
104. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA
105. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL
106. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of IκBα and IκBβ and sustained activation of nuclear factor-κ B/c-Rel
107. CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1
108. CpG DNA rescues B cells from apoptosis by activating NFκB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway
109. Unmethylated CpG motifs protect murine B lymphocytes against Fas-mediated apoptosis
110. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12
111. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens
112. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-γ production in cells from allergic individuals and inhibit IgE synthesis in vitro
113. Response of human monocyte-derived dendritic cells to immunostimulatory DNA
114. Bacterial CpG-DNA triggers activation and maturation of human CD11c(-), CD123(+) dendritic cells
115. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA
116. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
117. CpG motifs induce Langerhans cell migration in vivo
118. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal
119. The effects of DNA containing CpG motif on dendritic cells
120. CpG DNA and LPS induce distinct patterns of activation in human monocytes
121. Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides
122. Specific suppression of human tumor necrosis factor-α synthesis by antisense oligodeoxynucleotides
123. Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides
124. Intracisternally localized bacterial DNA containing CpG motifs induces meningitis
125. IFN-γ primes macrophage responses to bacterial DNA
126. Differential regulation of the IL-12 p40 promoter and of p40 secretion by CpG DNA and lipopolysaccharide
127. Cutting edge: Bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages
128. Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-γ production through activation of NF-κB
129. Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-α through a post-transcriptional mechanism
130. CpG DNA induces cyclooxygenase-2 expression and prostaglandin production
131. CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing
132. Phagocytic antigen processing and effects of products on antigen processing and T-cell responses
133. A novel function of phosphorothioate oligodeoxynucleotides as chemoattractants for primary macrophages
134. Immunostimulatory CpG-oligodeoxynucleotides induce a factor that inhibits macrophage adhesion
135. In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG
136. Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells
137. Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG
138. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length
139. Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro
140. Bacterial CpG DNA activates immune cells to signal infectious danger
141. CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells
142. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses
143. CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-γ production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12
144. Mycobacterium tuberculosis 19-kDa lipoprotein promotes neutrophil activation
145. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response
146. Specific antiviral activity demonstrated by TGTP, a member of a new family of interferon-induced GTPases
147. CpG motifs in Porphyromonas gingivalis DNA stimulate interleukin-6 expression in human gingival fibroblasts
148. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition
149. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ
150. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge
151. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
152. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation
153. Influence of base composition on membrane binding and cellular uptake of 10-mer phosphorothioate oligonucleotides in Chinese hamster ovary (CHRC5) cells
154. Identification of two oligodeoxyribonucleotide binding proteins on plasma membranes of human cell lines
155. The role of cell surface receptors in the activation of human B cells by phosphorothioate oligonucleotides
156. Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide
157. The influence of lipofectin on the in vitro stimulation of murine spleen cells by bacterial DNA and plasmid DNA vectors
158. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides
159. Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible
160. Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation
161. Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset
162. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes
163. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells
164. Identification and characterization of a cell membrane nucleic acid channel
165. Uptake and localization of phosphodiester and chimeric oligodeoxynucleotides in normal and leukemic primary cells
166. Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors?
167. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides
168. Intracellular localization of oligonucleotides: Influence of fixative protocols
169. Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogs
170. Rapid nuclear accumulation of injected oligodeoxyribonucleotides
171. Intracellular distribution of microinjected antisense oligonucleotides
172. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides
173. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
174. Pharmacokinetic properties of phosphorothioates in animals - Absorption, distribution, metabolism and elimination
175. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate
176. Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice
177. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species
178. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds
179. Structure-activity relationship analysis of substituted 4-quinolinamines, antagonists of immunostimulatory CpG-oligodeoxynucleotides
180. A toll-like receptor recognizes bacterial DNA
181. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9
182. Three novel mammalian toll-like receptors: Gene structure, expression, and evolution
183. Role of toll-like Receptor 9 in CpG DNA-induced activation of human cells
184. Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells
185. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs
186. Macrophages sense pathogens via DNA motifs: Induction of tumor necrosis factor-α-mediated shock
187. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA
188. Adjuvants for human vaccines - Current status, problems and future prospects
189. Biochemistry of antigen receptor signaling in mature and developing B lymphocytes
190. The complexity of signaling pathways activated by the BCR
191. Involvement of Ets, rel and Sp1-like proteins in lipopolysaccharide-mediated activation of the HIV-1 LTR in macrophages
192. Positive and negative regulatory elements contribute to CpG oligonucleotide-mediated regulation of human IL-6 gene expression
193. CpG ODN-mediated regulation of IL-12 p40 transcription
194. Bacterial DNA-induced NK cell IFN-γ production is dependent on macrophage secretion of IL-12
195. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract
196. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
197. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice
198. Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice
199. Use of immune modulators in nonspecific therapy of bacterial infections
200. Immunostimulants
201. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines
202. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria
203. Activation of the innate immune system by CpG oligodeoxynucleotides: Immunoprotective activity and safety
204. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection
205. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis
206. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12-and IFN-γ-dependent mechanisms
207. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
208. IL 12- and IFN-γ-dependent protection of mice against malaria conferred by CpG DNA
209. Immune recognition of foreign DNA: A cure for bioterrorism?
210. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor β 1 or Rb oligonucleotides
211. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis
212. Enhancing vaccines with immune stimulatory CpG DNA
213. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity
214. Antisense c-myc inhibition of lymphoma growth
215. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model
216. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously
217. Cationic lipid: Bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models
218. Antimetastatic effect of CpG DNA mediated by type I IFN
219. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs
220. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice
221. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs
222. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients
223. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins
224. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses
225. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
226. + T cell dependent
227. + T cells
228. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA
229. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines
230. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates
231. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
232. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor
233. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity
234. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice
235. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo
236. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma
237. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma
238. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens
239. Immunostimulatory CpG-oligonucleotides induce functional high-affinity IL-2 receptors on B-CLL cells: Costimulation with IL-2 results in a highly immunogenic phenotype
240. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma
241. Atopic disorders: A default pathway in the absence of infection?
242. Dietary nucleic acids promote a shift in Th1/Th2 balance toward Th1-dominant immunity
243. Nucleotides in infant nutrition: Effects on immune function
244. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
245. + T cells
246. CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism
247. Synthetic oligodeoxynucleotides inhibit IgE induction in human lymphocytes
248. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice
249. Long-term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides
250. Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice
251. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen
252. Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen
253. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma
254. The origin, sequence, structure, and consequences of developing anti-DNA antibodies. A human perspective
255. The immunologic properties of DNA
256. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice
257. The site and stage of anti-DNA B-cell deletion
258. Deletion and editing of B cells that express antibodies to DNA
259. Breakdown of B cell tolerance in a mouse model of systemic lupus erythematosus
260. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: A paradigm for autoimmune disease
261. Nucleosome-driven autoimmune response in lupus. Pathogenic T helper cell epitopes and costimulatory signals
262. Structural similarity of antibody variable regions from immune and autoimmune anti-DNA antibodies
263. Antigen-specific induction of antibodies against native mammalian DNA in nonautoimmune mice
264. In vivo expression of a single viral DNA-binding protein generates systemic lupus erythematosus-related autoimmunity to double-stranded DNA and histones
265. Experimental expression in mice and spontaneous expression in human SLE of polyomavirus T-antigen. A molecular basis for induction of antibodies to DNA and eukaryotic transcription factors
266. Effects of bacterial DNA on cytokine production by (NZB/NZW) F1 mice
267. Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA
268. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA
269. Do DNA vaccines induce autoimmune disease?
270. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: Mechanisms of selection of the self-reactive repertoire
271. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells
272. Microbial products induce autoimmune disease by an IL-12-dependent pathway
273. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo
274. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA
275. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: Modulation of T cell costimulation
276. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis
277. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis
278. Non-coding plasmid DNA induces IFN-γ in vivo and suppresses autoimmune encephalomyelitis
279. A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis
280. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines
281. A targeted DNA vaccine augments the natural immune response to self TNF-α and suppresses ongoing adjuvant arthritis
282. Chlamydia infections and heart disease linked through antigenic mimicry
283. Unmethylated oligo-DNA containing CpG motifs aggravates collagen-induced arthritis in
284. T cell-independent rescue of B lymphocytes from peripheral immune tolerance
285. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state
286. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-γ-secreting T cells after DNA-based immunization
287. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice
288. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis
289. The features of arthritis induced by CpG motifs in bacterial DNA
290. The major role of macrophages and their product tumor necrosis factor α in the induction of arthritis triggered by bacterial DNA containing CpG motifs
291. Chromosomal DNA from a variety of bacterial species is present in synovial tissue from patients with various forms of arthritis
292. Bacterial DNA causes septic shock
293. Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway
294. Antibodies to dsDNA are produced during primary BK virus infection in man, indicating that anti-dsDNA antibodies may be related to virus replication in vivo
295. Direct immunologic activities of CpG DNA and implications for gene therapy
296. Minding the Cs and Gs
297. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)